Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial on Efficacy of mTOR Inhibitor RAD001 as Maintenance Therapy for Patients Above 60 Years in Mantle Cell Lymphoma After First and Second Line Chemotherapy

NCT00727207 is registered in ClinicalTrials.gov with Technical University of Munich as lead sponsor.

NCT NCT00727207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00727207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial on Efficacy of mTOR Inhibitor RAD001 as Maintenance Therapy for Patients Above 60 Years in Mantle Cell Lymphoma After First and Second Line Chemotherapy
Lead sponsor
Technical University of Munich
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2008
Completion date
September 30, 2014
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma